- Dalal Street Corner: Softening crude, FIIs turning net buyers allow market to close on high note; what should investors do on Th
- Gold Price Outlook: Yellow metal on slippery ground; experts give intraday trading strategy, outlook
- Will oil prices surge to $380 or slump to $45—What JP Morgan, CITI reports say?
- MF industry's asset base rises 14% to Rs 37.75 lakh cr in June quarter
- TVS Motor drives in new bike 'Ronin' priced at Rs 1.49 lakh
Bristol-Myers Squibb Co`s
The failure of an Incyte immunotherapy drug in combination with Merck & Co`s
Gilead has a hefty $85 billion market capitalisation, making it only a target for the largest global drugmakers. Its product portfolio targets HIV/AIDS, hepatitis C, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. The company recently named a new CEO, Daniel O`Day, who previously headed Roche Holdings AG`s
Rare disease specialist Alexion, which has faced pressure from activist hedge fund Elliott Management could be an acquisition target for companies such as Amgen Inc
Raymond James analysts said in a research note that M&A could happen this year involving companies focussed on the huge unmet need for treating the progressive fatty liver disease known as NASH (non-alcoholic steatohepatitis), which does not yet have any approved treatments. Even though their shares did not get a boost on Thursday, Madrigal Pharmaceuticals
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
04:30 am